​

Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

ForecastRevenueOwnershipFinancialsChart
Enanta Pharmaceuticals by TradingView

Previous Close

$7.34

52W Range

$4.09 - $15.92

50D Avg

$6.98

200D Avg

$7.23

Market Cap

$158.19M

Avg Vol (3M)

$158.79K

Beta

0.85

Div Yield

-

ENTA Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

131

IPO Date

Mar 21, 2013

Website

ENTA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 24Sep 23Sep 21
Royalty$67.64M$78.20M$97.07M
License-$1.00M-

Fiscal year ends in Sep 24 | Currency in USD

ENTA Financial Summary

Sep 24Sep 23Sep 22
Revenue$67.64M$79.20M$86.16M
Operating Income$-121.69M$-137.21M$-123.84M
Net Income$-116.05M$-133.82M$-121.75M
EBITDA$-121.69M$-123.48M$-119.22M
Basic EPS$-5.48$-6.38$-5.91
Diluted EPS$-5.48$-6.38$-5.91

Fiscal year ends in Sep 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 24May 06, 24 | 4:30 PM
Q1 24Feb 07, 24 | 4:30 PM
Q4 23Nov 20, 23 | 4:30 PM

Peer Comparison

TickerCompany
MLYSMineralys Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
KROSKeros Therapeutics, Inc.
ERASErasca, Inc.
GLUEMonte Rosa Therapeutics, Inc.
XNCRXencor, Inc.
MGNXMacroGenics, Inc.
EWTXEdgewise Therapeutics, Inc.